Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atypical antipsychotic-induced metabolic syndrome study
2006-004034-32Phase 4Completed
- Sponsor
- Medical University of Graz
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of olanzapine, risperidone, aripiprazole, quetiapine and ziprasidone in schizophrenia, schizoaffective disorder and acute polymorphic psychotic disorder (APPD) (5 arms), sponsored by Medical University of Graz. Primary endpoints: Change in subcutaneous fat depot and Change in visceral fat depot. Started Oct 2006; status: completed.
02
Drugs
olanzapinerisperidonearipiprazolequetiapineziprasidone
03
Conditions
schizophreniaschizoaffective disorderacute polymorphic psychotic disorder (APPD)
Beyond the preview
Go deeper on 2006-004034-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004034-32.